CD30/TNFRSF8 Protein, Human, Recombinant (His Tag)

1/2
Price:
Size:
Number:

CD30/TNFRSF8 Protein, Human, Recombinant (His Tag): Product Information

Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Measured by its binding ability in a functional ELISA. Immobilized Human CD30L hFc (Cat:10040-H01H) at 2 μg/mL (100 μL/well) can bind Human CD30/TNFRSF8 His(Cat:10777-H08H), the EC50 of Human CD30/TNFRSF8 His is 30-180 ng/mL.
Protein Construction
A DNA sequence encoding the human TNFRSF8 (NP_001234.2) extracellular domain (Met 1-Lys 379) was expressed, fused with a polyhistidine tag at the C-terminus.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Phe 19
Molecule Mass
The secreted recombinant human TNFRSF8 consists of 372 amino acids and has a predicted molecular mass of 40 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhTNFRSF8 is approximately 75-90 kDa due to glycosylation.
Formulation
Lyophilized from sterile PBS, pH 7.4
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CD30/TNFRSF8 Protein, Human, Recombinant (His Tag): Images

Measured by its binding ability in a functional ELISA. Immobilized Human CD30L hFc (Cat:10040-H01H) at 2 μg/mL (100 μL/well) can bind Human CD30/TNFRSF8 His(Cat:10777-H08H), the EC50 of Human CD30/TNFRSF8 His is 30-180 ng/mL.

CD30/TNFRSF8 Protein, Human, Recombinant (His Tag): Synonyms

CD30 Protein, Human; D1S166E Protein, Human; Ki-1 Protein, Human

CD30/TNFRSF8 Background Information

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor (TNFR) superfamily. CD30 protein is expressed by activated, but not resting, T and B cells. CD30 can regulate proliferation of lymphocytes and may also play an important role in human immunodeficiency virus replication. As a regulator of apoptosis, CD30 protein induces cell death or proliferation, depending on the cell type, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. CD30 protein expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs), and CD30 is also linked to leukocytes in patients with chronic inflammatory diseases, including lupus erythematosus, asthma, rheumatoid arthritis and atopic dermatitis (AD).
Full Name
tumor necrosis factor receptor superfamily, member 8
Research Areas
References
  • Rossi FM, et al. (2001) CD30L up-regulates CD30 and IL-4 expression by T cells. FEBS Lett. 508(3): 418-22.
  • Trovato M, et al. (2001) Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules. Thyroid. 11(7): 621-8.
  • Ekstrom ES, et al. (2001) Presence of CD30(+) and CD30L(+) cells in human placenta and soluble CD30 levels in cord blood are independent of maternal atopy. Placenta. 22(4): 372-9.
  • Tang C, et al. (2008) A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J Immunol. 181(9): 6316-27.
  • Sun X, et al. (2008) A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology. 134(2): 447-58.
  • Oflazoglu E, et al. (2009) Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases.Adv Exp Med Biol. 647: 174-85.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.